Gennaro Ciliberto

Istituto Nazionale Tumori IRCCS.“Fondazione G. Pascale”, Naples, Italy; University of Catanzaro “Magna Graecia”, Catanzaro, Italy.

Career
1978 M.D. Univ of Napoli "Federico II, July, 1979-1987 Post doc Fellow EMBL Heidelberg Napoli, 1987-1990 Associate professor in Genetics Univ of Pisa, 1990 Full Professor of Molecular BiologyUniv of Napoli, Faculty of Pharmacy in year 1990. In year 1995 moved to Univ of Catanzaro. 1991-Sep 2009 On leave of absence from University due to employment at the Merck Sharp and Dohme research center IRBM P. Angeletti in Pomezia (Rome) 2006-2009 Site Head and Managing Director IRBM P. Angeletti in Pomezia, Rome. Nov 2009 co-founder of a biotechnology company, Takis s.r.l., a spin-off of the IRBM P. Angeletti, with the main focus on research and development of Cancer Immunotherapies. Oct 2009-Feb 2012 Univ of Catanzaro Magna Graecia March 2012 to October 2016 Scientific Director of IRCSS Istituto Nazionale Tumori, "G. Pascale" Napoli. Italy Since November 2016 Scientific Director of IRCCS Istituto Nazionale Tumori "Regina Elena", Rome, Italy

Memberships and Recognitions
Since 1989 elected member of the European Molecular Biology Organization (EMBO). January 2013- December 2016 President of SIBBM (Società Italiana di Biofisica e Biologia Molecolare) Since January 2016 President of FISV (Italian Federation of Scientific Societies of Life Sciences). Past member (years 2012-2016 of Italian National Committee of Biotechnology, Biosafety and Life Sciences (CNBBSV).

Publications and scientific interests
Co-author of more than 350 indexed publications (total I.F. > 1700; H-index =70) (Source: Scopus) and 30 between book chapters and editorials. Large experience in Technology transfer as witnessed by Co-inventor of 30 international granted patents/patent applications Reviewer and editorial board member of several international journals (Journal of Immunotherapy of Cancer. Journal of Translational Medicine, Cell Death and Differentiations, Cancers) and editor of textbook for graduate students.
Current main scientific interests are: a) study of the mechanisms responsible for drug resistance in melanoma; b) alterations of lipid metabolism in cancer, mainly lung cancer; c) personalized therapy of cancer; d) genetic vaccines for the therapy of cancer.